Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

healthstream inc. - HSTM

HSTM

Close Chg Chg %
32.19 0.34 1.06%

Closed Market

32.53

+0.34 (1.06%)

Volume: 170.24K

Last Updated:

Nov 25, 2024, 4:00 PM EDT

Trade Now

Company Overview: healthstream inc. - HSTM

HSTM Key Data

Open

$32.45

 Day Range

32.37 - 33.09

52 Week Range

23.92 - 33.09

 Market Cap

$979.06M

Shares Outstanding

30.41M

 Public Float

24.02M

Beta

0.35

 Rev. Per Employee

N/A

P/E Ratio

49.82

 EPS

$0.65

Yield

33.86%

 Dividend

$0.03

EX-DIVIDEND DATE

Nov 4, 2024

 SHORT INTEREST

N/A

AVERAGE VOLUME

144.38K

  

HSTM Performance

1 Week
 
 1.06%
 
1 Month
 
 14.91%
 
3 Months
 
 12.99%
 
1 Year
 
 26.09%
 
5 Years
 
 11.67%
 

HSTM Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 7
Full Ratings ➔

About healthstream inc. - HSTM

HealthStream, Inc. engages in the provision of services to healthcare organizations. It develops healthcare technology platforms for workforce solutions. The firm’s workforce solutions include learning management, nurse & staff scheduling, clinical education, credentialing, privileging, provider enrollment, performance assessment, and managing simulation-based education programs. The company was founded by Robert A. Frist, Jr. and Jeffery L. McLaren in 1990 and is headquartered in Nashville, TN.

HSTM At a Glance

HealthStream, Inc.
500 11th Avenue North
Nashville, Tennessee 37203-2015
Phone 1-615-301-3100 Revenue 279.06M
Industry Packaged Software Net Income 15.21M
Sector Technology Services 2023 Sales Growth 4.586%
Fiscal Year-end 12 / 2024 Employees 1,079
View SEC Filings

HSTM Valuation

P/E Current 49.822
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 54.496
Price to Sales Ratio 2.971
Price to Book Ratio 2.403
Price to Cash Flow Ratio 12.961
Enterprise Value to EBITDA 13.682
Enterprise Value to Sales 2.799
Total Debt to Enterprise Value 0.03

HSTM Efficiency

Revenue/Employee 258,631.14
Income Per Employee 14,099.166
Receivables Turnover 7.259
Total Asset Turnover 0.559

HSTM Liquidity

Current Ratio 1.10
Quick Ratio 1.10
Cash Ratio 0.601

HSTM Profitability

Gross Margin 51.231
Operating Margin 5.74
Pretax Margin 6.633
Net Margin 5.451
Return on Assets 3.05
Return on Equity 4.509
Return on Total Capital 4.18
Return on Invested Capital 4.235

HSTM Capital Structure

Total Debt to Total Equity 6.815
Total Debt to Total Capital 6.38
Total Debt to Total Assets 4.645
Long-Term Debt to Equity 5.942
Long-Term Debt to Total Capital 5.563
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Healthstream Inc. - HSTM

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
244.83M 256.71M 266.83M 279.06M
Sales Growth
-3.65% +4.85% +3.94% +4.59%
Cost of Goods Sold (COGS) incl D&A
119.52M 127.85M 129.09M 136.10M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
30.19M 36.81M 37.95M 41.08M
Depreciation
6.90M 6.30M 4.50M 4.20M
Amortization of Intangibles
23.29M 30.51M 33.45M 36.88M
COGS Growth
-9.29% +6.97% +0.97% +5.43%
Gross Income
125.31M 128.87M 137.74M 142.97M
Gross Income Growth
+2.41% +2.84% +6.88% +3.80%
Gross Profit Margin
+51.18% +50.20% +51.62% +51.23%
2020 2021 2022 2023 5-year trend
SG&A Expense
109.49M 120.81M 125.29M 126.95M
Research & Development
32.30M 41.66M 44.28M 45.54M
Other SG&A
77.18M 79.15M 81.01M 81.41M
SGA Growth
+1.78% +10.34% +3.71% +1.32%
Other Operating Expense
- - - -
-
Unusual Expense
- (1.18M) 183.00K (2.85M)
EBIT after Unusual Expense
17.00M 7.87M 15.30M 16.02M
Non Operating Income/Expense
824.00K (106.00K) 287.00K 2.49M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
17.82M 7.77M 15.59M 18.51M
Pretax Income Growth
-0.59% -56.43% +100.68% +18.77%
Pretax Margin
+7.28% +3.03% +5.84% +6.63%
Income Tax
3.73M 1.92M 3.49M 3.30M
Income Tax - Current - Domestic
(635.00K) 411.00K 2.90M 5.01M
Income Tax - Current - Foreign
71.00K (29.00K) (110.00K) 15.00K
Income Tax - Deferred - Domestic
4.30M 1.63M 734.00K (1.71M)
Income Tax - Deferred - Foreign
(1.00K) (86.00K) (25.00K) (18.00K)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
14.09M 5.84M 12.09M 15.21M
Minority Interest Expense
- - - -
-
Net Income
14.09M 5.84M 12.09M 15.21M
Net Income Growth
-0.74% -58.52% +106.86% +25.82%
Net Margin Growth
+5.76% +2.28% +4.53% +5.45%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
14.09M 5.84M 12.09M 15.21M
Preferred Dividends
- - - -
-
Net Income Available to Common
14.09M 5.84M 12.09M 15.21M
EPS (Basic)
0.4409 0.1854 0.3945 0.4976
EPS (Basic) Growth
+0.55% -57.95% +112.78% +26.13%
Basic Shares Outstanding
31.96M 31.53M 30.65M 30.57M
EPS (Diluted)
0.4405 0.1849 0.3936 0.496
EPS (Diluted) Growth
+0.62% -58.02% +112.87% +26.02%
Diluted Shares Outstanding
31.99M 31.62M 30.72M 30.67M
EBITDA
46.01M 44.87M 50.39M 57.09M
EBITDA Growth
+7.87% -2.48% +12.32% +13.30%
EBITDA Margin
+18.79% +17.48% +18.89% +20.46%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 32.00
Number of Ratings 7 Current Quarters Estimate 0.132
FY Report Date 12 / 2024 Current Year's Estimate 0.627
Last Quarter’s Earnings 0.19 Median PE on CY Estimate N/A
Year Ago Earnings 0.50 Next Fiscal Year Estimate 0.642
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 6 5 6 6
Mean Estimate 0.13 0.15 0.63 0.64
High Estimates 0.14 0.17 0.63 0.68
Low Estimate 0.13 0.13 0.62 0.59
Coefficient of Variance 3.10 10.54 0.82 5.52

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 2 2 2
OVERWEIGHT 1 1 1
HOLD 4 4 4
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Healthstream Inc. - HSTM

Date Name Shares Transaction Value
Jun 7, 2024 Terry Allison Rappuhn Director 2,252 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 7, 2024 Deborah Taylor Tate Director 2,252 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 7, 2024 Alex Jahangir Director 2,252 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 7, 2024 Alex Jahangir Director 1,125 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 7, 2024 Linda Eskind Rebrovick Director 2,252 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 7, 2024 Linda Eskind Rebrovick Director 54,900 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 7, 2024 Frank E. Gordon Director 206,467 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 7, 2024 Terry Allison Rappuhn Director 3,782 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 7, 2024 Thompson Smith Dent Director 2,252 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 7, 2024 Thompson Smith Dent Director 133,546 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 7, 2024 William W. Stead Director 2,252 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 7, 2024 William W. Stead Director 41,879 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 7, 2024 Jeffrey L. McLaren Director 2,252 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 7, 2024 Jeffrey L. McLaren Director 19,319 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 7, 2024 Deborah Taylor Tate Director 23,726 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 7, 2024 Frank E. Gordon Director 2,252 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 2, 2024 Scott Fenstermacher Senior Vice President 13,008 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $26.19 per share 340,679.52
Feb 28, 2024 Kevin P. O'Hara Senior Vice President 8,844 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 28, 2024 Kevin P. O'Hara Senior Vice President 8,478 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $26.81 per share 227,295.18
Feb 28, 2024 Kevin P. O'Hara Senior Vice President 8,500 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Healthstream Inc. in the News